Table 1 Clinical and paraclinical data as well as therapeutic details for jDM and aDM patients
From: Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis
Age (mean ± SD) | juvenile (n = 15) | adult (n = 21) | NC (n = 10) | |
|---|---|---|---|---|
8 +/−4 years | 57 +/−15 years | 7 +/−6 years and 45 +/−11 years | ||
Gender | female | 47 % (7) | 67 % (14) | 30 % (3) |
male | 53 % (8) | 33 % (7) | 70 % (7) | |
Biopsy location | M. deltoideus | 57 % (12) | 50 % (5) | |
M. quadriceps | 87 % (13) | 5 % (1) | ||
unknown | 13 % (2) | 38 % (8) | 50 % (5) | |
CK | normal | 20 % (3) | 14 % (3) | 100 % (10) |
>1-fold | 60 % (9) | 29 % (6) | ||
>10-fold | 13 % (2) | 38 % (8) | ||
unknown | 7 % (1) | 19 % (4) | ||
Symptoms | typical skin rash | 73 % (11) | 52 % (11) | |
dysphagia | 20 % (3) | 10 % (2) | 20 % (2)a | |
muscle weakness | 73 % (11) | 67 % (14) | 20 % (2)a | |
muscle pain | 60 % (9) | 52 % (11) | 50 % (5)a | |
others | 27 % (4) | 38 % (8) | ||
unknown | 13 % (2) | 5 % (1) | ||
Duration of | in months | 5 +/−4 (11) | 3 +/−3 (10) | 7 +/−1 (4) |
symptoms | >1 years | 7 % (1) | 5 % (1) | 20 % (2) |
unknown | 20 % (3) | 48 % (10) | 19 % (4) | |
Tubuloreticular formations (EM) | positive | 53 % (8) | 76 % (16) | n.d. |
unknown | 47 % (7) | 24 % (5) | ||
MSAs | positive | 7 % (1) | 19 % (4) | n.d. |
negative | 67 % (10) | 33 % (7) | ||
unknown | 26 % (4) | 48 % (10) | ||
Clinical outcome | remission | 53 % (8) | 29 % (6) | |
improvement | 20 % (3) | 10 % (2) | ||
remitting-relapsing | 27 % (4) | 10 % (2) | ||
no improvement | 0 % (0) | 5 % (1) | ||
unknown | 0 % (0) | 48 % (10) | 100 % (10) |